MetaCap

Evolus (EOLS) vs Ovid Therapeutics (OVID)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ovid Therapeutics (OVID) has outperformed Evolus (EOLS) over the past year, gaining 57.1% versus a loss of 4.8%. Over five years, EOLS leads with a +14.4% price change compared with -32.5% for OVID. Evolus is the larger company by market cap ($431.5 million vs $415.2 million), about 1.0 times the size, while Ovid Therapeutics is growing revenue faster (+1181.3% vs +11.6%).

Evolus converts more of its revenue into profit, with a net margin of -17.4% versus -240.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EOLS-4.82%OVID+57.14%
+119%+34%-50%
Nov 21, 20251 yearNov 20, 2026
EOLS+2.19%OVID-36.05%
+187%+41%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EOLS versus OVID key metrics
MetricEOLSOVID
Share price$6.52$2.20
Market cap$431.55M$415.21M
1-day change-6.86%-5.98%
YTD return-1.95%+34.97%
1-year return-4.82%+57.14%
5-year return+14.39%-32.52%
Forward P/E22.68—
EPS (TTM)$-0.48$-0.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$297.18M$7.25M
Revenue growth (YoY)+11.61%+1181.27%
Net income (latest FY)$-51.64M$-17.41M
Gross margin66.33%—
Operating margin-10.99%-585.20%
Net margin-17.38%-240.13%
52-week high$9.31$3.11
52-week low$3.86$1.26
Distance from 52-week high-29.97%-29.15%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+136.20%+179.55%
Average volume925.77K1.98M
Shares outstanding66.19M188.73M
Employees36523
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OVID has outperformed EOLS by 62.0 percentage points over the past year.
  • Evolus is more profitable, keeping -17.4 cents of every revenue dollar as net income versus -240.1 cents for Ovid Therapeutics.
  • Ovid Therapeutics grew revenue faster in its latest fiscal year (+1181.27% vs +11.61%).

About Evolus

EOLS stock →

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.

Health Care · Biotechnology: Pharmaceutical Preparations · 365 employees

About Ovid Therapeutics

OVID stock →

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

EOLS vs OVID FAQ

Which is bigger, Evolus or Ovid Therapeutics?

Evolus (EOLS) is larger, with a market capitalization of $431.55M compared with $415.21M for Ovid Therapeutics (OVID).

Which stock has performed better over the past year, EOLS or OVID?

OVID returned +57.14% over the past 12 months, compared with -4.82% for EOLS (price return, excluding dividends). Past performance does not predict future results.

Are Evolus and Ovid Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons